Bijoy Hans Limited is an India-based company. The Company is mainly engaged in the business of trading in bulk drugs, pharmaceuticals, cosmetics and investment. The Company offers various pharmaceutical formulations, such as tablets, capsules, syrups, suspension and powders, focusing on segments, such as Antibiotics, Cough/ Cold/ Allergy. H-1 Receptor Antagonist (Antiulcerant), Nutraceuticals and NSAIDS.
Arvaya Healthcare Limited Financial Highlights
- Revenue: Arvaya Healthcare Limited reported revenue of ₹0.17 crore in FY26 vs ₹0.47 crore in FY25. It showed a decrease of 63.83% on a yearly basis.
- Operating Profit: Arvaya Healthcare Limited reported an operating loss of ₹1.20 crore in FY26 vs ₹0.19 crore in FY25. It showed a decrease of 731.58% on a year-on-year basis.
- Net Profit: Arvaya Healthcare Limited reported a net loss of ₹1.20 crore in FY26 vs ₹0.14 crore in FY25. It showed a decrease of 957.14% on a yearly basis.
Arvaya Healthcare Limited Quarterly Result Highlights
- Arvaya Healthcare Limited reported revenue of ₹0.07 crore in Mar 2026, compared with ₹0.05 crore in Dec 2025, representing an increase of 40.00% on a quarter-on-quarter (QoQ) basis.
- Arvaya Healthcare Limited reported an operating loss of ₹0.63 crore in Mar 2026, compared with ₹0.16 crore in Dec 2025, representing a decrease of 293.75% on a quarter-on-quarter (QoQ) basis.
- Arvaya Healthcare Limited reported a loss of ₹0.63 crore in Mar 2026, compared with ₹0.16 crore in Dec 2025, reflecting a decrease of 293.75% on a QoQ basis.
- The earnings per share (EPS) of Arvaya Healthcare Limited stood at ₹0.45 during Mar 2026.